Payment overview · 2025
General Payments
$248.49
14 reported records · 8 companies
Healthcare provider profile · identity verified
Bobby Aaron Thompson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PARAGOULD, AR · NPI 1720020662
Verified facts
What the public records show
CMS Open Payments records show Bobby Aaron Thompson, M.D. received $248.49 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.96 | 32.2% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.18 | 14.6% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $29.84 | 12.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.12 | 11.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.32 | 8.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.43 | 7.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.23 | 7.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.41 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.49 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.18 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $29.84 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $29.84 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.87 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.12 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 317 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 307 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 64 |
| Gabapentin | Gabapentin | 218 | 38 |
| Furosemide | Furosemide | 216 | 47 |
| Alprazolam | Alprazolam | 184 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 42 |
| Simvastatin | Simvastatin | 154 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 33 |
| Metformin Hcl | Metformin Hcl | 149 | 36 |
| Eliquis | Apixaban | 135 | 21 |
| Omeprazole | Omeprazole | 135 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 37 |
| Meloxicam | Meloxicam | 129 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 22 |
| Montelukast Sodium | Montelukast Sodium | 110 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 22 |
| Tramadol Hcl | Tramadol Hcl | 98 | 25 |
| Losartan Potassium | Losartan Potassium | 97 | 22 |
| Potassium Chloride | Potassium Chloride | 97 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 24 |
| Atenolol | Atenolol | 83 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 15 |
| Carvedilol | Carvedilol | 80 | 19 |
| Diazepam | Diazepam | 78 | 13 |
| Famotidine | Famotidine | 73 | 18 |
| Pregabalin | Pregabalin | 67 | 13 |
| Glipizide | Glipizide | 65 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 11 |
| Finasteride | Finasteride | 60 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 11 |
| Ozempic | Semaglutide | 58 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 41 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 15 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 15 |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Azithromycin | Azithromycin | 47 | 42 |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 13 |
| Clonidine Hcl | Clonidine Hcl | 44 | 16 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Cefdinir | Cefdinir | 43 | 37 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Naproxen | Naproxen | 41 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 20 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 22 |
| Nystatin | Nystatin | 39 | 19 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 11 |
| Rybelsus | Semaglutide | 36 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 12 |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.49 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, Kerendia, PAXLOVID, QULIPTA, TRELEGY ELLIPTA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error